Skip to Content

Portage Biotech Inc PRTG Stock Quote

| Rating as of

Morningstar‘s Stock Analysis PRTG

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics PRTG

Company Profile PRTG

Business Description

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Contact
Craigmuir Chambers, Tortola
Road Town, VG1110, Virgin Islands, British
T +1 416 929-1806
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Mar 31, 2023
Stock Type
Employees 6